Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic highlights positive study data for CoreValve system

Medtronic highlights positive study data for CoreValve system

21st February 2011

Medtronic's aortic valve disease treatment system CoreValve has had its efficacy endorsed by a newly-published independent study.

The report, which was conducted in Italy and appears in the medical journal Circulation, has confirmed the early and sustained clinical benefits provided by the minimally invasive therapy option.

Analysing data from 663 aortic stenosis patients, the trial demonstrated that the device was associated with substantial improvements of cardiac function, as well as a 98 percent procedural success rate.

CoreValve was approved in Europe in 2007 and has been implanted in more than 12,000 patients to date, with Medtronic currently seeking US approval of the device.

Dr John Liddicoat, vice-president and general manager of the structural heart division at Medtronic, said: "We are committed to supporting clinical evaluation of the CoreValve system to offer patients with severe aortic stenosis the safest and most adequate technique for treating this disease."

This month, the company also published data revealing that its Kyphon Balloon Kyphoplasty treatment for spine fractures has demonstrated its effectiveness during a two-year study.ADNFCR-8000103-ID-800417472-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.